Background
==========

Pancreatic benign tumors are now found more frequently due to the improvement of radiological technology. Some kinds of pancreatic benign lesions, such as intraductal papillary mucinous neoplasm (IPMN), high-grade pancreatic intraepithelial neoplasia, and pancreatic endocrine neoplasm, have the potential for malignant transformation or can be accompanied with stubborn symptoms and are recommended to be resected by the surgeons.

But the choosing of surgical methods is still sometimes controversial, especially for lesions located in the neck or the proximal body of pancreas. Choosing the best surgical method is challenging for surgeons. Traditional distal pancreatectomies are most common, but always result in removal of a large piece of normal pancreatic tissue, and also increase the risk of exocrine and endocrine insufficiency. Enucleation is also another option, but it increases the risk of injury of the main pancreatic tube, long-term postoperative pancreatic fistula (POPF), readmission and reoperation, ad needing extend resections. Middle pancreatectomy is a parenchyma-sparing procedure for the lesions located in the neck or the proximal body of the pancreas, aiming to reduce the rate of postoperative exocrine and endocrine insufficiency. Elderly people have higher risk of postoperative pancreas dysfunction because of tissue or organ degeneration, so it is more important for them to reserve pancreas parenchyma.

The first laparoscopic MP was reported in 2003 \[[@b1-medscimonit-21-2851]\], but it is still not widely used because of the technical complexity and high rate of postoperative fistula. The development of a robotic surgical system is a milestone for the application of minimally invasive technique for pancreatic surgeries. It complements some defects of traditional laparoscopic technique and brings patients more precise treatment, less harm, and faster recovery, especially for elderly people. In this article, we retrospectively assessed 10 robot-assisted middle pancreatectomies for patients who were over 60 years old, and we discuss the indications, safety, feasibility, and short- and long-term outcomes of robot-assisted MPs for elderly patients.

Material and Methods
====================

Patients
--------

In our center, from Aug 2012 to May 2015, a total of 10 patients who underwent robot-assisted middle pancreatectomy were retrospectively evaluated (study group). The same major surgeon performed all the operations. The mean age of the robotic group was 64.30±4.95 years. The mean BMI was 21.20±2.35. There were 7 males and 3 females. The baseline demographic characteristics of the patients are shown in [Table 1](#t1-medscimonit-21-2851){ref-type="table"}. Eight patients had no symptoms and the other 2 were diagnosed because of unresolved epigastric pain. All patients received ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and other essential tests to locate the tumor and rule out surgery contradictions. All 10 lesions were located in the neck or proximal body of the pancreas ([Figure 1B](#f1-medscimonit-21-2851){ref-type="fig"}). The follow-up period was defined as the interval between the day of operation and the day of the last follow-up; the follow-up endpoint in this study was 1 May 2015. Outpatients were followed-up by telephone interviews. Exocrine deficiency was defined as steatorrhea or eating, combined with epigastrium pain and weight loss requiring pancreatic enzyme supplementation. Endocrine dysfunction means the postoperative new onset of Type 2 diabetes mellitus (T2DM) or worsening diabetes (defined as deterioration in the metabolic control of previously diagnosed diabetes, requiring modification of the medical treatment).

We also reviewed another 55 patients who underwent robot-assisted middle pancreatectomies in the same period as a control group. We compared the perioperative parameters and follow-up data of both groups.

Definition of POPF
------------------

Amylase activity in the abdominal drain output was routinely measured every other day beginning on postoperative day 3 and continuing until drain removal. According to the International Study Group on Pancreatic Fistula (ISGPF) criteria, POPF was defined as "a drain output of any measurable volume of fluid on or after postoperative day 3 with amylase content greater than 3 times the serum amylase activity". Grade A POPFs, also termed "transient fistulas", do not require special treatment or prolonged hospital stays. Grade B POPFs require nothing by mouth (NPO), enteral or parenteral nutrition, and prolonged drain maintenance; CT scans may show peripancreatic collection(s), and grade B POPFs are always complicated by sepsis that requires antibiotics. Grade C POPFs are the most serious and are characterized by intra-abdominal collections, sepsis, and multiple organ failure and usually require admission to the intensive care unit (ICU) and reoperation.

Surgical procedures
-------------------

### Patient position and ports placement

Patients were was positioned in the supine position with legs apart and were placed in a 20° reverse Trendelenburg position. Pneumo-peritoneum was established using a Veress needle. The intra-abdominal pressure was usually 15 mmHg. Five ports were used, positioned along a semicircular arc facing the epigastrium. One 12-mm camera port, one 12-mm operating port for the assistant, and three 8-mm working ports were placed. The 12-mm camera port was placed approximately 0.5 cm up to the umbilicus. The scope was introduced to rule out any injury, and a 30° laparoscope was usually used. Under vision, the other three 8-mm robotic trocars and one 12-mm robotic trocar were placed ([Figure 1A](#f1-medscimonit-21-2851){ref-type="fig"}). The 12-mm assistant port was used for suction and instrument introduction. The major surgeon was seated at the robotic console, while one assistant surgeon was positioned at the left side of the patient.

Middle pancreatectomy
---------------------

The ultrasonic scalpel was used to open the gastrocolic ligament ([Figure 2A](#f2-medscimonit-21-2851){ref-type="fig"}) and then we exposed the pancreas by lifting and retracting the posterior gastric wall by the fourth robotic arm ([Figure 2B](#f2-medscimonit-21-2851){ref-type="fig"}). Following this step, we generally could recognize the tumor and next exposed and dissected the portal vein (PV) at the superior edge of the pancreatic neck and the superior mesenteric vein (SMV) at the inferior edge of the neck of pancreas. Along with the vascular axis, the retropancreatic tunnel was carefully established ([Figure 2C, 2D](#f2-medscimonit-21-2851){ref-type="fig"}). Then, the pancreatic neck was transected using the ultrasonic scalpel. The proximal stump was intermittently sutured with polypropylene 4-0 for homeostasis and preventing POPF ([Figure 3A](#f3-medscimonit-21-2851){ref-type="fig"}). The distal pancreas was carefully dissected between the pancreas and the splenic vessels. Then, we transected the pancreas on the left side of the tumor with the ultrasonic scalpel. The distal pancreas was dissected about 2 or 3 cm for achieving pancreaticogastrostomy with no tension. We carried out 2-layer end-to-side pancreaticogastrostomy for reconstruction. First, we inserted a stent into the pancreatic tube for drainage, hoping to prevent the stenosis of anastomosis ([Figure 3B](#f3-medscimonit-21-2851){ref-type="fig"}) because it always increases the risk the POPF and pancreatitis \[[@b2-medscimonit-21-2851]\]. Then the outer layer of posterior wall was performed with intermittent stitches of 4-0 Prolene sutures from the pancreatic parenchyma to the seromuscular layer ([Figure 3C](#f3-medscimonit-21-2851){ref-type="fig"}). After that, a 3--4 cm incision was made at the posterior wall of gastric body using the electric hook and the inner layer of the posterior wall was performed with intermittent stitches of 4-0 Prolene sutures from the stump of the pancreatic remnant to the full layer of the gastric body ([Figure 3D](#f3-medscimonit-21-2851){ref-type="fig"}). The anastomosis of the posterior wall was completed. Next, we inserted the stent into the gastric lumen and performed the anastomosis of the anterior wall in the same way ([Figure 3E, 3F](#f3-medscimonit-21-2851){ref-type="fig"}). Two drainage tubes were placed near the proximal pancreatic stump and the anastomosis.

Literature review
-----------------

We performed a literature search using PubMed, including data from 2010--2015. Key words of searching were "middle pancreatectomy", "central pancreatectomy", and "median pancreatectomy". Only original research with at least 20 cases of MPs were included. Studies about minimally invasive middle pancreatotomies with more than 10 cases were reviewed considering the few reports and small sample sizes. For duplicated multiple publications of the same cohort of patients, only the most recent one was used. Two of the 10 authors (Tian Zhang and Xinjing Wang) reviewed all the retrieved studies meeting the inclusion criterion and extracted data on the following events: first author, year of publication, number of patients, mean age, patient sex, number, severity of pancreatic fistula, exocrine of endocrine insufficiency, and time of follow-up. Pancreatic fistula was defined and classified according to the ISGPF principle.

Statistics
----------

Results are presented as mean ±SD, including intraoperative parameters, postoperative parameters, postoperative complications and perioperative mortality. Data analysis was performed using SPSS version 19.0.

Results
=======

Perioperative data
------------------

From Aug 2012 to May 2015, 10 consecutive robot-assisted middle pancreatectomies were performed in our center. The 10 lesions were all benign or low-grade malignant with no organ or vessel invasion and no metastasis. The mean operating time was 175.00±45.28 min (range, 120--240 min). No conversion occurred. The mean blood loss was 113.00±107.09 ml (range, 30--400 ml). No patient required blood transfusion. The mean tumor size was 2.61±1.51 cm (range, 1--6 cm, data not shown). The mean time of oral intake was 2.12±1.13 d (range, 1--4 days, data not shown). Five patients had POPFs, including 2 Grade A fistulas and 3 Grade B fistulas. Patients with grade B POPFs recovered by nothing by mouth (NPO), parenteral nutrition, and prolonged drain maintenance. Postoperative complications happened in 3 patients. Two patients had postoperative infections and recovered using antibiotics (Clavien Dindo Classification Grade 1 or 2). The other 1 had both postoperative infection and bile leak, and recovered with antibiotic therapy and endoscopic nose biliary drainage (ENBD) (Grade 3). The mean hospital stay was 19.91±8.85 d (range, 9--42 days). All patients' symptoms resolved completely and no mortality occurred ([Table 2](#t2-medscimonit-21-2851){ref-type="table"}).

Postoperative pathology presented 3 IPMNs, 4 serous cystadenomas, 2 pancreatic endocrine neoplasms (G1), and 1 mucinous cystadenoma.

At the same time, there was no significant difference in age, BMI, ALB, blood-loss, operating time, tumor size, rate of POPF, postoperative complications, reoperation, time of tumor removal, and post-operative hospital stay between the study group and control group, but the study group had more patients who had previously diagnosed T2DM ([Table 3](#t3-medscimonit-21-2851){ref-type="table"}).

In the control group, there were 28 serous cystadenomas, 11 solid pseudopapillary tumor, 5 pancreatic endocrine neoplasms (G1), 5 IPMNs, 4 mucinous cystadenomas, 1 PIN, and 1 lipoma (pancreas invasion).

Follow-up information
---------------------

Up to 1 May 2015, the median follow-up time was 23 months (range, 2--35 m). No clear tumor recurrence was identified by CTA during the follow-up examinations. New onset of T2DM happened in 1 patient, requiring oral hypoglycemic drugs (OHAs) treatment but not insulin administration. No deterioration of previously diagnosed T2DM occurred. No patients developed new onset of exocrine insufficiency ([Table 2](#t2-medscimonit-21-2851){ref-type="table"}).

For the control group, 4 patients suffered from new onset of T2DM, requiring OHAs treatment. No exocrine insufficiency developed ([Table 3](#t3-medscimonit-21-2851){ref-type="table"}).

Literature review
-----------------

Ten studies about open middle pancreatectomies involving 376 patients were included. An overview database of these studies is shown in [Table 4](#t4-medscimonit-21-2851){ref-type="table"}. All these studies were retrospective studies. The sample sizes were all greater than 20. Of all the patients, 38% (range 14.2 to 63) suffered from POPFs, including 75 grade A fistulas and 98 grade B or C fistulas. Incidence of reoperation was 3.5%, and postoperative morbidity and mortality were 162 and 3, respectively. Thirty-two patients had exocrine or endocrine insufficiency ([Table 4](#t4-medscimonit-21-2851){ref-type="table"}).

Five studies about minimally invasive middle pancreatectomies involving 65 cases were reviewed. All studies were retrospective studies. POPFs occurred in 46.2% (range 13.3 to 92.3) of all patients, including 13 grade A fistulas and 17 grade B or C fistulas. Two patients suffered from reoperations, and postoperative morbidity and mortality were 38.5% and 0, respectively. No patients (data of one study was not available) developed exocrine or endocrine insufficiency ([Table 4](#t4-medscimonit-21-2851){ref-type="table"}).

Discussion
==========

The first segmental pancreatic resection was performed by Oskar Ehrhardt in 1908 \[[@b3-medscimonit-21-2851]\]. In 1957, Guillemin and Bessot first reported a middle pancreatic (MP) resection with the pancreaticojejunostomy. It has been increasingly used for benign or low-grade malignant tumors located in the neck and proximal body of the pancreas. MP is still an uncommon surgical procedure because of the relatively high risk of postoperative fistula and procedural complexity. This may because: 1) the proximal and the distal pancreatic stump both have the risk of fistula and 2) the MPs are always applied to the benign pancreatic lesions located in the neck of the pancreas and the texture of such pancreas is always "soft", thus contributing to the increased pancreatic fistula rate. However, MP is a parenchyma-sparing procedure and has the advantage of conserving exocrine and endocrine function. Some retrospective studies have shown MP is safe and POPF can be managed successfully by conservative measures or mini-invasive approaches despite the relatively high risk of fistulas, although there have been few RCTs about the perioperative or long-term outcome comparing MP and distal pancreatectomy.

Since the first application of MP, the high POPF risk of this technique has always concerned surgeons, thus restraining the developing of MP \[[@b4-medscimonit-21-2851],[@b5-medscimonit-21-2851]\]. The Mannheim Clinic series demonstrated that nearly 20% of postoperative deaths should be attributed to pancreatic fistula \[[@b6-medscimonit-21-2851]\], which helps explain why MP has not become a regular procedure for partial pancreatectomy, unlike distal pancreatectomy. However, with the improvement of recognition to POPF, middle pancreatectomies are increasingly used all over the world, as are laparoscopic MPs, because surgeons care more about preserving postoperative pancreatic function, especially for patients with benign or low-grade malignant tumors. Enucleation is an ideal surgery for pancreatic benign tumors, but it has a high risk of bile tract or pancreatic duct injury and also has a high rate of POPF \[[@b7-medscimonit-21-2851]\]. Distal pancreatectomy always sacrifices a large amount of normal pancreatic tissue and has risk of splenic vascular injury, as well as the high risk of POPF at the same time \[[@b8-medscimonit-21-2851],[@b9-medscimonit-21-2851]\].

Laparoscopic pancreatic resection has been increasingly used since the 1990s \[[@b10-medscimonit-21-2851]\], but there are still some barriers to the wide application of MP. Many patients needing MPs have been treated with open surgeries of traditional distal pancreatectomies \[[@b11-medscimonit-21-2851]\]. Some surgeons are concerned about the high risk of POPFs. Another obstacle restraining the developing of MP is the complexity of the laparoscopic procedure, so laparoscopic pancreatectomy has rarely been reported \[[@b12-medscimonit-21-2851]--[@b17-medscimonit-21-2851]\]. The robotic surgical system overcomes some defects of traditional laparoscopic technique and has been used for pancreatic surgeries \[[@b18-medscimonit-21-2851]--[@b21-medscimonit-21-2851]\]. This is mainly because: 1) The 3-dimensional and magnified view allows surgeons to sense the depth of field better and observe subtle structures more clearly; 2) The 7 degrees of freedom machine arms ease suturing, stanching, and other procedures; thus, the learning curve considerably decreases; 3) It filters the natural hand quiver, which makes operations safer; and 4) Less trauma allows patients to recover faster \[[@b22-medscimonit-21-2851]--[@b24-medscimonit-21-2851]\]. Thus, minimally invasive pancreatic surgeries have become common, even some particularly complex procedures requiring vascular dissection or reconstruction \[[@b25-medscimonit-21-2851],[@b26-medscimonit-21-2851]\]. Giulianotti reported the first case of robot-assisted MP in 2004 \[[@b27-medscimonit-21-2851]\]. However, studies comparing robot-assisted MPs and open surgeries are rare. In 2011, our center published a retrospective study on robot-assisted MP. We demonstrated that robot-assisted MP was safe and feasible and that patients may benefit from quicker gastrointestinal tract recovery \[[@b21-medscimonit-21-2851]\]. In another previous study of our center, we demonstrated that robot-assisted surgery had the advantage of preserving splenic vasculature \[[@b18-medscimonit-21-2851]\].

Laugier reported that pancreatic exocrine changes with patient age. Aging alters pancreatic secretion. Pancreatic exocrine insufficiency due to ageing occurs through a decrease in flow rate, and bicarbonate and enzyme secretion \[[@b28-medscimonit-21-2851]\]. In addition, the exocrine and endocrine functions of the pancreas have close anatomical and functional links between each other and any disease impairing one of them will inevitably affect the other \[[@b29-medscimonit-21-2851]\]. Matteo determined that pancreatic exocrine insufficiency was common in diabetics, with a wide range in both type I diabetes mellitus (25--74%) and T2DM (28--54%) \[[@b30-medscimonit-21-2851]\]. Therefore, it is important for elderly people to preserve the pancreatic parenchyma, preventing new onset of pancreatic dysfunction or deterioration of previously diagnosed pancreatic diseases.

From Aug 2012, our center did 10 consecutive robot-assisted middle pancreatectomies for elderly patients who suffered from pancreatic benign of low-grade malignant tumors locating in the neck of pancreas. Our perioperative database was comparable with reports of other centers. We had 5 patients with POPF, including 2 Grade A fistulas and 3 Grade B fistulas according the ISGPF criterion. Because Grade A fistula does not require intervention, the "true" postoperative fistula rate in our study was 30%, which is equal or less than those of other centers ([Table 3](#t3-medscimonit-21-2851){ref-type="table"}). Postoperative complications occurred in 3 patients. Two patients had intra-abdominal infection and recovered by antibiotic treatment. The other 1 had intra-abdominal infection and bile leak, accepting ENBD. The overall rate of morbidity was 30%, also comparable with these of other reports ([Table 3](#t3-medscimonit-21-2851){ref-type="table"}). The 3 patients all had Grade B fistulas. These results prove that Grade B or C fistula can result in relatively severe complications but poor outcomes can be prevented by a variety of appropriate therapies. Moreover, there was only 1 new onset of T2DM and no deterioration of previously diagnosed diabetes or exocrine insufficiency happened. Burkhart reported that 29% (23/78) of patients accepting distal pancreatectomies suffered from new onset of diabetes mellitus (NODM) \[[@b31-medscimonit-21-2851]\]. Recently, De Bruijn reviewed 26 studies about distal pancreatectomy. The incidence of NODM after distal pancreatectomy performed for chronic pancreatitis was 39% and for benign or (potentially) malignant tumors it was 14%. Insulin treatment was accepted by 77% of patients with NODM \[[@b32-medscimonit-21-2851]\]. In our study, we had a lower rate of NODM, but the difference was not statistically significant (data not shown). Patients can benefit from this kind of surgery, but given the small sample size, we require more practice to prove its feasibility.

In our study, the mean hospital stay was a little longer than that in other reports. This is mainly because our community health service system is still progressing, and patients are not discharged until they completely recover, including removal of the drainage tube and 1--2 days of observation. These factors seem to increase the hospital stay.

The present study has some defects. 1) It was not an RCT and the sample size was small, so bias is inevitable. 2) The same surgeon performed all of the operations, but different physicians provided postoperative care, and some aspects of the perioperative management may have varied slightly.

Conclusions
===========

Robot-assisted middle pancreatectomy is safe and feasible for use in elderly people. It not only alleviates the surgical harm, but also effectively decreases exocrine or endocrine insufficiency of the pancreas. Although this technique has a relatively high risk of postoperative pancreatic fistula, poor outcomes could be prevented with suitable therapies. Larger series and RCTs are necessary to fully prove these potential advantages.

**Source of support:** Departmental surces

![(**A**) Locations of trocars. C: camera port. R1: no. 1 machine arm. R2: no. 2 machine arm. R3: no. 3 machine arm. A: assistant port. (**B**) Typical tumor revealed by abdominal computed tomography. The arrow indicates the tumor.](medscimonit-21-2851-g001){#f1-medscimonit-21-2851}

![(**A**) Opening the gastrocolic ligament. (**B**) Pancreas exposure. (**C**) Vascular exposure at the superior edge of the pancreatic body. (**D**) SMV exposure at the inferior edge of the pancreatic body. SMV, superior mesenteric vein](medscimonit-21-2851-g002){#f2-medscimonit-21-2851}

![(**A**) Stent inserted. (**B**) The proximal stump of pancreas is sutured. (**C**) The outer layer of posterior wall is sutured. (**D**) The inner layer of posterior wall is sutured. (**E**) The inner layer of anterior wall is sutured. (**F**) The outer layer of anterior wall is sutured. SMV, superior mesenteric vein.](medscimonit-21-2851-g003){#f3-medscimonit-21-2851}

###### 

Baseline demographic characteristics of the patients.

  No.          Age (y)      Sex   BMI          ALB (g/L)    TB (μmol/L)   DM
  ------------ ------------ ----- ------------ ------------ ------------- ----
  1            62           M     23.38        39           20.4          0
  2            60           M     19.10        41           7.1           1
  3            71           M     23.42        45           19.6          0
  4            61           F     19.56        43           10.9          1
  5            73           M     18.28        40           16.6          0
  6            69           M     18.37        33           12.8          0
  7            60           M     24.48        42           18            0
  8            60           F     22.13        34           16.1          0
  9            65           F     24.41        36           7.4           1
  10           62           M     20.76        40           9             0
  Mean value   64.30±4.95   /     21.20±2.35   39.30±3.89   13.80±5.10    /

BMI -- body mass index; M -- male; F -- female; ALB -- albumin; TB -- total bilirubin DM -- diabetes mellitus.

###### 

Perioperative and postoperative parameters.

  No.          Blood loss (ml)   Operative time (min)   Blood transfusion   POPF   Complication              Hospital stay (d)   New onset or deterioration of DM   Exocrine insufficiency   Time of follow-up (m)   Reope-ration   Mortality
  ------------ ----------------- ---------------------- ------------------- ------ ------------------------- ------------------- ---------------------------------- ------------------------ ----------------------- -------------- -----------
  1            100               220                    /                   /      /                         15                  /                                  /                        33                      /              /
  2            150               240                    /                   /      /                         17                  Yes                                /                        32                      /              /
  3            400               200                    /                   /      /                         21                  /                                  /                        28                      /              /
  4            50                120                    /                   A      /                         26                  /                                  /                        24                      /              /
  5            100               150                    /                   /      /                         13                  /                                  /                        22                      /              /
  6            50                170                    /                   B      Infection                 24                  /                                  /                        19                      /              /
  7            100               200                    /                   B      Infection                 21                  /                                  /                        18                      /              /
  8            50                210                    /                   B      Infection and bile leak   42                  /                                  /                        11                      /              /
  9            30                120                    /                   A      /                         16                  /                                  /                        2                       /              /
  10           100               120                    /                   /      /                         9                   /                                  /                        1                       /              /
  Mean value   113.00 ±107.09    175.00 ±45.28          /                   /      /                         19.91 ±8.85         /                                  /                        /                       /              /

POPF -- post-operative pancreatic fistula; DM -- diabetes mellitus.

###### 

Intraoperative data and postoperative outcomes.

  Event                        Study group (n=10)   Control group (n=55)   P value
  ---------------------------- -------------------- ---------------------- -------------------------------------------------------------
  Gender (M/F)                 7/3                  15/40                  0.024[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
  Age                          64.30±4.95           44.91±11.44            \<0.001[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  BMI                          21.53±2.40           22.57±3.13             0.998[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  ALB                          39.10±3.90           41.20±3.33             0.573[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  Diabetes                     3/7                  1/54                   0.010[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
  Operating time (min)         175.00±50.07         174.44±70.63           0.917[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  Blood loss (ml)              113.00±107.09        100.75±79.96           0.645[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  Blood transfusion            0                    0                      1.000[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
  Tumor size (cm)              2.55±1.52            2.49±1.28              0.578[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  POPF                         5                    31                     0.547[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
   Grade A                     2                    11                     
   Grade B                     3                    18                     
   Grade C                     0                    4                      
  Complication                 3                    18                     1.000[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
   Grade 1--2                  2                    13                     
   Grade 3--5                  1                    5                      
  Reoperation                  0                    4                      1.000[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
  Time of drain-tube-off (d)   16.60±8.43           18.81±9.97             0.007[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  Postoperative stay (d)       19.91±9.16           22.86±11.89            0.358[\*](#tfn4-medscimonit-21-2851){ref-type="table-fn"}
  Exocrine insufficiency       0                    53                     1.000[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
  Endocrine insufficiency      1                    4                      0.579[\*\*](#tfn5-medscimonit-21-2851){ref-type="table-fn"}
   New onset of diabetes       1                    4                      
   Worsening diabetes          0                    0                      

Male -- male; F -- female; BMI -- body mass index; ALB -- albumin; POPF -- post-operative pancreatic fistula.

Unpaired t test;

Chi-square test.

###### 

Literature review on the occurrence and severity of pancreatic fistula and pancreatic dysfunction after middle pancreatectomy.

  Reference                                                                                                 Year   No. of patients   Male/female   POPF        POPF Grade (A/B/C)   Reoperation   Morbidity    Mortality   Pancreatic insufficiency (Exo/Endo)
  --------------------------------------------------------------------------------------------------------- ------ ----------------- ------------- ----------- -------------------- ------------- ------------ ----------- -------------------------------------
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Cataldegirmen et al. \[[@b33-medscimonit-21-2851]\]   2010   35                17/18         5 (14.2)    −/−/−                0             9 (26)       0           3/2
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} DiNorcia et al. \[[@b34-medscimonit-21-2851]\]        2010   73                20/53         15 (20.5)   3/7/5                0             30 (41.1)    0           −/10
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} LaFemina et al. \[[@b35-medscimonit-21-2851]\]        2010   23                8/15          6 (26)      5/1/0                0             8 (34.8)     0           0/0
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Shikano et al. \[[@b36-medscimonit-21-2851]\]         2010   26                14/12         8 (31)      2/5/1                0             10 (38)      0           1/0
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Dumitrascu et al. \[[@b37-medscimonit-21-2851]\]      2012   24                8/16          10 (41.6)   3/5/2                2             13 (54.2)    0           −/−
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Venara et al. \[[@b38-medscimonit-21-2851]\]          2012   25                18/7          12 (48)     4/3/5                5             10 (40)      0           0/3
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Xiang et al. \[[@b39-medscimonit-21-2851]\]           2012   44                16/28         24 (54.5)   12/11/1              --            --           0           −/2
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Yvain et al. \[[@b40-medscimonit-21-2851]\]           2014   100               33/67         63 (63)     19/40/4              6             72           3           6/2
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Song et al. \[[@b41-medscimonit-21-2851]\]            2014   26                --            --          --                   --            10           --          0/3
  [1](#tfn6-medscimonit-21-2851){ref-type="table-fn"} Jasper et al. \[[@b42-medscimonit-21-2851]\]          2015   20                --            8 (40)      −/8 (B+C)            --            --           --          --
  [2](#tfn7-medscimonit-21-2851){ref-type="table-fn"} Amer et al. \[[@b43-medscimonit-21-2851]\]            2013   13                --            12 (92.3)   2/9/1                1             13 (100.0)   0           --
  [2](#tfn7-medscimonit-21-2851){ref-type="table-fn"} Safi et al. \[[@b44-medscimonit-21-2851]\]            2013   13                --            9 (69.2)    4/2/2                0             10 (76.9)    0           0/0
  [2](#tfn7-medscimonit-21-2851){ref-type="table-fn"} Chen et al. \[[@b13-medscimonit-21-2851]\]            2014   15                2/13          2 (13.3)    2/0/0                0             0 (0)        0           0/0
  [2](#tfn7-medscimonit-21-2851){ref-type="table-fn"} Hong et al. \[[@b45-medscimonit-21-2851]\]            2015   10                --            3 (30.0)    3/0/0                1             1 (10.0)     0           0/0
  [2](#tfn7-medscimonit-21-2851){ref-type="table-fn"} Senthilnathan et al. \[[@b46-medscimonit-21-2851]\]   2015   14                6/8           4 (28.6)    2/2/0                0             4 (28.6)     0           2/0

Open middle pancreatectomy;

minimally invasive middle pancreatotomy.

POPF -- post-operative pancreatic fistula; Exo -- exocrine insufficiency; Endo -- endocrine insufficiency.
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